Skip to main content
Fig. 1 | BMC Women's Health

Fig. 1

From: Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients

Fig. 1

Patients inclusion/exclusion process and treatment pattern of bevacizumab. Abbreviations: FL group, patients receiving bevacizumab as first-line chemotherapy; NT group, patients receiving bevacizumab during NACT alone; NT + FL group, patients receiving bevacizumab during both neoadjuvant and first-line chemotherapy; FLA group, patients receiving bevacizumab during first-line chemotherapy alone; RT group, patients receiving bevacizumab as recurrence therapy

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us